Axel Grothey mainly focuses on Internal medicine, Colorectal cancer, Oncology, Oxaliplatin and Clinical trial. His research investigates the connection between Internal medicine and topics such as Surgery that intersect with issues in Placebo. His work carried out in the field of Colorectal cancer brings together such families of science as Survival rate, Gastroenterology, Disease, Proportional hazards model and Bevacizumab.
His Oncology study incorporates themes from Cetuximab, Metastasis, Survival analysis and Hazard ratio. The study incorporates disciplines such as Calcium and Pharmacology in addition to Oxaliplatin. The Clinical trial study combines topics in areas such as Meta-analysis, Adjuvant, Randomized controlled trial and Adverse effect.
His scientific interests lie mostly in Internal medicine, Oncology, Colorectal cancer, Oxaliplatin and Clinical trial. Much of his study explores Internal medicine relationship to Surgery. His biological study spans a wide range of topics, including Regorafenib, Adverse effect, Adjuvant therapy and Hazard ratio.
He usually deals with Regorafenib and limits it to topics linked to Placebo and Clinical endpoint. His Colorectal cancer research integrates issues from Metastasis, Fluorouracil and Disease. The various areas that he examines in his Oxaliplatin study include Gastroenterology, Regimen, Capecitabine and Pharmacology.
His primary areas of study are Internal medicine, Colorectal cancer, Oncology, Cancer research and Cancer. All of his Internal medicine and Clinical trial, Oxaliplatin, Regorafenib, Adverse effect and Disease investigations are sub-components of the entire Internal medicine study. His study in the fields of Cetuximab, Irinotecan, FOLFIRI and KRAS under the domain of Colorectal cancer overlaps with other disciplines such as Text mining.
Many of his research projects under Oncology are closely connected to In patient with In patient, tying the diverse disciplines of science together. His Cancer research research incorporates themes from Immunohistochemistry, Missense mutation, Pd l1 expression, Microsatellite instability and Gene. His research in Cancer intersects with topics in Gastroenterology, Overall survival, Cohort and Stage.
Axel Grothey mostly deals with Internal medicine, Colorectal cancer, Oncology, Binimetinib and Encorafenib. His study in Clinical trial, Cancer, Clinical endpoint, Adverse effect and Regorafenib are all subfields of Internal medicine. His Colorectal cancer research incorporates elements of Cancer research, Trastuzumab, Survival rate, Mutant and Sunitinib.
His research integrates issues of Stage, KRAS, Chemotherapy and FOLFIRI in his study of Oncology. His studies deal with areas such as Oxaliplatin and FOLFOX as well as Chemotherapy. His Binimetinib research is multidisciplinary, incorporating perspectives in Cetuximab, BRAF V600E and Irinotecan.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem;A. Cervantes;R. Adam;A. Sobrero.
Annals of Oncology (2016)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey;Eric Van Cutsem;Alberto Sobrero;Salvatore Siena.
The Lancet (2013)
Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data
Anna D. Wagner;Wilfried Grothe;Johannes Haerting;Gerhard Kleber.
Journal of Clinical Oncology (2006)
Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
Daniel J. Sargent;Silvia Marsoni;Genevieve Monges;Stephen N. Thibodeau.
Journal of Clinical Oncology (2010)
Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy
Scott Kopetz;George J. Chang;Michael J. Overman;Cathy Eng.
Journal of Clinical Oncology (2009)
Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment
Axel Grothey;Daniel Sargent;Richard M. Goldberg;Hans Joachim Schmoll.
Journal of Clinical Oncology (2004)
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Nicole M. Kuderer;Toni K. Choueiri;Dimpy P. Shah;Yu Shyr.
The Lancet (2020)
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Al B. Benson;Alan P. Venook;Lynette Cederquist;Emily Chan.
Journal of The National Comprehensive Cancer Network (2017)
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study
Josep Tabernero;Takayuki Yoshino;Allen Lee Cohn;Radka Obermannova.
Lancet Oncology (2015)
Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
Axel Grothey;Mary M. Sugrue;David M. Purdie;Wei Dong.
Journal of Clinical Oncology (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: